News | May 30, 2024
Merck to acquire EyeBio for US$ 1.3 billion upfront payment
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
Additional data from APPRAISE ATP trial reinforce modular therapy approach
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
EBITDA before special items falls 1.3 percent to € 4.41 billion
Aptar Closures’ E-Disc Top securely protects against in-transit leakage while eliminating the need for liners and extra shipping preparation fees
The brand has also unveiled a new TVC campaign in Telangana and Andhra Pradesh to drive brand awareness
TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer
Subscribe To Our Newsletter & Stay Updated
